Adamantinoma
| Adamantinoma | |
 | |
|---|---|
| Micrograph of an adamantinoma showing the biphasic histomorphology. H&E stain.. | |
| ICD-O: | 9310/0 |
| DiseasesDB | 31676 |
| MeSH | D050398 |
|
WikiDoc Resources for Adamantinoma |
|
Articles |
|---|
|
Most recent articles on Adamantinoma Most cited articles on Adamantinoma |
|
Media |
|
Powerpoint slides on Adamantinoma |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Adamantinoma at Clinical Trials.gov Clinical Trials on Adamantinoma at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Adamantinoma
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Adamantinoma Discussion groups on Adamantinoma Patient Handouts on Adamantinoma Directions to Hospitals Treating Adamantinoma Risk calculators and risk factors for Adamantinoma
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Adamantinoma |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Adamantinoma is a rare bone cancer, making up less than 1% of all bone cancers. It predominantly arises in bone in a subcutaneous location (85% are in the tibia). Most commonly, patients are in their second or third decade, but it can occur over a wide age range.
Historical Perspective
The condition was first described by Fischer in 1913.[1][2]
Prior name for ameloblastoma
The typically benign odontogenic tumor known as ameloblastoma was first recognized in 1827 by Cusack but did not yet have any designation.[3] In 1885, this kind of odontogenic neoplasm was designated as an adamantinoma by Malassez[4] and was finally renamed to the modern name ameloblastoma in 1930 by Ivey and Churchill.[5][6] Some authors still confusingly misuse the term adamantinoma to describe ameloblastomas, however they differ in histology and frequency of malignancy.
Pathophysiology
Histologically, islands of epithelial cells are found in a fibrous stroma.
Treatment
Treatment consists of wide resection or amputation. Metastases are rare at presentation but may occur in up to 30% of patients during the disease course. Prognosis is excellent, with overall survival of 85% at 10 years, but is lower when wide surgical margins cannot be obtained.
References
- Campbell's Operative Orthopedics (10th edition ed.). 2003.